Patch testing in a case of eslicarbazepine and carbamazepine induced cutaneous reaction

  • Eur Ann Allergy Clin Immunol. 2018 Sep;50(5):229-231. doi: 10.23822/EurAnnACI.1764-1489.37.
E Finelli  1 ,  P Custódio  1 ,  O Porovska  2 ,  S Prates  1 ,  P Leiria-Pinto  1
Affiliations
  • 1. Immunoallergology Department, Dona Estefânia Hospital, Centro Hospitalar Lisboa Central, Lisbon, Portugal.
  • 2. Occupational Health Department, São José Hospital, Centro Hospitalar Lisboa Central, Lisbon, Portugal.
PMID: 29384108 DOI: 10.23822/EurAnnACI.1764-1489.37
Abstract

Anticonvulsants are among the drugs most commonly involved in cutaneous adverse drug reactions (CADRs). Eslicarbazepine is a new anti-epileptic drug, chemically related to carbamazepine but with a more favorable safety profile. We report the clinical case of a woman who developed a skin rash on day 10 of eslicarbazepine with further exacerbation with eosinophilia on day 2 of carbamazepine. Epicutaneous tests were positive with eslicarbazepine.

Keywords
anticonvulsant drugs; drug allergy; epicutaneous tests; eslicarbazepine; skin rash.
Products